

# James H Maccabe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5627910/publications.pdf>

Version: 2024-02-01

227  
papers

10,853  
citations

50170

46  
h-index

42291

92  
g-index

253  
all docs

253  
docs citations

253  
times ranked

12809  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reducing the Risk of Withdrawal Symptoms and Relapse Following Clozapine Discontinuationâ€”Is It Feasible to Develop Evidence-Based Guidelines?. <i>Schizophrenia Bulletin</i> , 2022, 48, 176-189.	2.3	19
2	The temporal dynamics of sleep disturbance and psychopathology in psychosis: a digital sampling study. <i>Psychological Medicine</i> , 2022, 52, 2741-2750.	2.7	8
3	Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. <i>British Journal of Psychiatry</i> , 2022, 220, 115-120.	1.7	81
4	Clozapine treatment and risk of severe COVID-19 infection. <i>Acta Psychiatrica Scandinavica</i> , 2022, 145, 79-85.	2.2	6
5	Neuropsychological differences between treatment-resistant and treatment-responsive schizophrenia: a meta-analysis. <i>Psychological Medicine</i> , 2022, 52, 1-13.	2.7	14
6	Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia. <i>JAMA Psychiatry</i> , 2022, 79, 260.	6.0	44
7	COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine. <i>European Neuropsychopharmacology</i> , 2022, 56, 92-99.	0.3	4
8	Using a statistical learning approach to identify sociodemographic and clinical predictors of response to clozapine. <i>Journal of Psychopharmacology</i> , 2022, 36, 498-506.	2.0	5
9	Ethnic inequalities in clozapine use among people with treatment-resistant schizophrenia: a retrospective cohort study using data from electronic clinical records. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2022, 57, 1341-1355.	1.6	7
10	Subcortical volume reduction and cortical thinning 3 months after switching to clozapine in treatment resistant schizophrenia. <i>NPJ Schizophrenia</i> , 2022, 8, 13.	2.0	6
11	Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis. <i>NPJ Schizophrenia</i> , 2022, 8, 21.	2.0	23
12	Real-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort study. <i>British Journal of Psychiatry</i> , 2022, 221, 740-747.	1.7	6
13	Duration of prior psychotic illness and clozapine response: a retrospective observational study using electronic health records. <i>Therapeutic Advances in Psychopharmacology</i> , 2022, 12, 204512532211033.	1.2	3
14	Impaired verbal memory function is related to anterior cingulate glutamate levels in schizophrenia: findings from the STRATA study. , 2022, 8, .		1
15	Relaxation of the criteria for entry to the UK Clozapine Central Non-Rechallenge Database: a modelling study. <i>Lancet Psychiatry</i> , 2022, 9, 636-644.	3.7	13
16	Clozapine treatment and risk of COVID-19 infection: retrospective cohort study. <i>British Journal of Psychiatry</i> , 2021, 219, 368-374.	1.7	72
17	Cost and health impacts of adherence to the National Institute for Health and Care Excellence schizophrenia guideline recommendations. <i>British Journal of Psychiatry</i> , 2021, 218, 224-229.	1.7	11
18	Augmentation of clozapine with ECT: a retrospective case analysis. <i>Acta Neuropsychiatrica</i> , 2021, 33, 31-36.	1.0	9

#	ARTICLE	IF	CITATIONS
19	Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA). <i>Schizophrenia Bulletin</i> , 2021, 47, 505-516.	2.3	51
20	Predictors of treatment resistant schizophrenia: a systematic review of prospective observational studies. <i>Psychological Medicine</i> , 2021, 51, 44-53.	2.7	38
21	Psychotic experiences, psychiatric comorbidity and mental health need in the general population: a cross-sectional and cohort study in Southeast London. <i>Psychological Medicine</i> , 2021, 51, 147-157.	2.7	17
22	Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia. <i>Schizophrenia Bulletin</i> , 2021, 47, 662-671.	2.3	39
23	Investigating Patient Acceptability of Stratified Medicine for Schizophrenia: A Mixed Methods Study. <i>Schizophrenia Bulletin Open</i> , 2021, 2, sgab016.	0.9	1
24	There Is Life After the UK Clozapine Central Non-Rechallenge Database. <i>Schizophrenia Bulletin</i> , 2021, 47, 1088-1098.	2.3	24
25	DNA methylation meta-analysis reveals cellular alterations in psychosis and markers of treatment-resistant schizophrenia. <i>ELife</i> , 2021, 10, .	2.8	72
26	The association of migration and ethnicity with use of the Improving Access to Psychological Treatment (IAPT) programme: a general population cohort study. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2021, 56, 1943-1956.	1.6	7
27	Point-of-care measurement of clozapine concentration using a finger-stick blood sample. <i>Journal of Psychopharmacology</i> , 2021, 35, 279-283.	2.0	18
28	Demographic and clinical variables associated with response to clozapine in schizophrenia: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2021, 51, 376-386.	2.7	21
29	Peripheral immune markers and antipsychotic non-response in psychosis. <i>Schizophrenia Research</i> , 2021, 230, 1-8.	1.1	29
30	Early intervention in psychosis during the COVID-19 pandemic: Maudsley recommendations. <i>European Neuropsychopharmacology</i> , 2021, 47, 130-135.	0.3	6
31	Gender disparities in clozapine prescription in a cohort of treatment-resistant schizophrenia in the South London and Maudsley case register. <i>Schizophrenia Research</i> , 2021, 232, 68-76.	1.1	17
32	Clozapine-induced myocarditis: electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracy. <i>British Journal of Psychiatry</i> , 2021, 219, 644-651.	1.7	16
33	Seeing is believing. <i>Acta Psychiatrica Scandinavica</i> , 2021, 144, 3-5.	2.2	0
34	Predictors of clozapine discontinuation at 2+ years in treatment-resistant schizophrenia. <i>Schizophrenia Research</i> , 2021, 235, 102-108.	1.1	6
35	Attrition in longitudinal studies among patients with schizophrenia and other psychoses; findings from the STRATA collaboration. <i>Psychiatry Research</i> , 2021, 305, 114211.	1.7	8
36	Outcomes in treatment-resistant schizophrenia: symptoms, function and clozapine plasma concentrations. <i>Therapeutic Advances in Psychopharmacology</i> , 2021, 11, 204512532110371.	1.2	5

#	ARTICLE	IF	CITATIONS
37	Clozapine Response in Schizophrenia and Hematological Changes. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 19-24.	0.7	14
38	Cross-sectional study comparing cognitive function in treatment responsive versus treatment non-responsive schizophrenia: evidence from the STRATA study. <i>BMJ Open</i> , 2021, 11, e054160.	0.8	2
39	Clozapine-induced myocarditis: electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracy – ERRATUM. <i>British Journal of Psychiatry</i> , 2021, 219, 695-695.	1.7	2
40	Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2020, 34, 3-78.	2.0	259
41	Effect of single dose N-acetylcysteine administration on resting state functional connectivity in schizophrenia. <i>Psychopharmacology</i> , 2020, 237, 443-451.	1.5	9
42	Pharmacoepidemiology research: delivering evidence about drug safety and effectiveness in mental health. <i>Lancet Psychiatry</i> , 2020, 7, 363-370.	3.7	23
43	T19. GLUTAMATE AND RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2020, 46, S238-S238.	2.3	0
44	M212. A SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL VARIABLES ASSOCIATED WITH RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2020, 46, S217-S217.	2.3	0
45	Should Patients' Values Be Discussed in Relation to Long-Term Blood Monitoring Before and During Clozapine Treatment?. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 409-410.	0.7	0
46	Academic achievement and schizophrenia: a systematic meta-analysis. <i>Psychological Medicine</i> , 2020, 50, 1949-1965.	2.7	45
47	The association between neighbourhood characteristics and physical victimisation in men and women with mental disorders. <i>BJPsych Open</i> , 2020, 6, e73.	0.3	6
48	P.118 Longitudinal DNA methylation changes associated with improvement of psychotic symptoms during clozapine treatment. <i>European Neuropsychopharmacology</i> , 2020, 31, S13-S14.	0.3	0
49	Real-world effectiveness of admissions to a tertiary treatment-resistant psychosis service: 2-year mirror-image study. <i>BJPsych Open</i> , 2020, 6, e82.	0.3	6
50	Clozapine-induced agranulocytosis. <i>Annals of Hematology</i> , 2020, 99, 2477-2482.	0.8	58
51	The physical health and side-effect monitoring of patients prescribed clozapine: data from a clinical audit conducted in UK mental health services. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532093790.	1.2	6
52	S62. COGNITIVE DEFICITS IN TREATMENT RESISTANT SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2020, 46, S56-S57.	2.3	1
53	Schizophrenia polygenic risk predicts general cognitive deficit but not cognitive decline in healthy older adults. <i>Translational Psychiatry</i> , 2020, 10, 422.	2.4	19
54	Evaluation of the Cost-effectiveness of Services for Schizophrenia in the UK Across the Entire Care Pathway in a Single Whole-Disease Model. <i>JAMA Network Open</i> , 2020, 3, e205888.	2.8	17

#	ARTICLE	IF	CITATIONS
55	Consensus statement on the use of clozapine during the COVID-19 pandemic. <i>Journal of Psychiatry and Neuroscience</i> , 2020, 45, 222-223.	1.4	102
56	Clozapine and COVID-19: The authors respond. <i>Journal of Psychiatry and Neuroscience</i> , 2020, 45, E1-E2.	1.4	1
57	Management of clozapine treatment during the COVID-19 pandemic. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532092816.	1.2	34
58	Sleep and Circadian Rhythm Disturbance in Remitted Schizophrenia and Bipolar Disorder: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2020, 46, 1126-1143.	2.3	83
59	A Systematic Review of Economic Models Across the Entire Schizophrenia Pathway. <i>Pharmacoeconomics</i> , 2020, 38, 537-555.	1.7	6
60	A retrospective study of intramuscular clozapine prescription for treatment initiation and maintenance in treatment-resistant psychosis. <i>British Journal of Psychiatry</i> , 2020, 217, 506-513.	1.7	16
61	Effect of age on the relative efficacy of clozapine in schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2020, 142, 109-120.	2.2	13
62	The side effect profile of Clozapine in real world data of three large mental health hospitals. <i>PLoS ONE</i> , 2020, 15, e0243437.	1.1	28
63	Consensus statement on the use of clozapine during the COVID-19 pandemic. <i>Journal of Psychiatry and Neuroscience</i> , 2020, 45, 200061.	1.4	30
64	The side effect profile of Clozapine in real world data of three large mental health hospitals. , 2020, 15, e0243437.		0
65	The side effect profile of Clozapine in real world data of three large mental health hospitals. , 2020, 15, e0243437.		0
66	The side effect profile of Clozapine in real world data of three large mental health hospitals. , 2020, 15, e0243437.		0
67	The side effect profile of Clozapine in real world data of three large mental health hospitals. , 2020, 15, e0243437.		0
68	Clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study. <i>Acta Psychiatrica Scandinavica</i> , 2019, 139, 237-247.	2.2	51
69	The relationship between nicotine and psychosis. <i>Therapeutic Advances in Psychopharmacology</i> , 2019, 9, 204512531985996.	1.2	52
70	T66. PREDICTING TREATMENT RESISTANT SCHIZOPHRENIA AT FIRST-EPISODE OF PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2019, 45, S229-S230.	2.3	1
71	Stratified medicine in schizophrenia: how accurate would a test of drug response need to be to achieve cost-effective improvements in quality of life?. <i>European Journal of Health Economics</i> , 2019, 20, 1425-1435.	1.4	12
72	THE IMPACT OF THE DUFFY-NULL GENOTYPE IN CLOZAPINE-ASSOCIATED NEUTROPENIA: A GENOME-WIDE ASSOCIATION STUDY IN INDIVIDUALS OF AFRICAN ANCESTRY. <i>European Neuropsychopharmacology</i> , 2019, 29, S1031.	0.3	0

#	ARTICLE	IF	CITATIONS
73	The impact of clozapine initiation and cessation on psychiatric hospital admissions and bed days: a mirror image cohort study. <i>Psychopharmacology</i> , 2019, 236, 1931-1935.	1.5	20
74	Clozapine Treatment and Offending: A Within-Subject Study of Patients With Psychotic Disorders in Sweden. <i>Schizophrenia Bulletin</i> , 2019, 46, 303-310.	2.3	12
75	6.3 DOES TOBACCO SMOKING CAUSE PSYCHOSIS?. <i>Schizophrenia Bulletin</i> , 2019, 45, S96-S96.	2.3	0
76	Pharmacogenomic Variants and Drug Interactions Identified Through the Genetic Analysis of Clozapine Metabolism. <i>American Journal of Psychiatry</i> , 2019, 176, 477-486.	4.0	54
77	39â€¦The immunomodulatory effect of clozapine in patients with treatment resistant schizophrenia: a retrospective cohort study. , 2019, , .		0
78	P029â€¦Sleep and circadian rhythm disturbances and relapse in schizophrenia: a digital phenotyping study. , 2019, , .		4
79	Hyoscine for clozapine-induced hypersalivation. <i>International Clinical Psychopharmacology</i> , 2019, 34, 101-107.	0.9	8
80	Clozapine Rechallenge Following Neuroleptic Malignant Syndrome. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 372-379.	0.7	10
81	Need to bleed? Clozapine haematological monitoring approaches a time for change. <i>International Clinical Psychopharmacology</i> , 2019, 34, 264-268.	0.9	13
82	A genome-wide association study in individuals of African ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropenia. <i>Molecular Psychiatry</i> , 2019, 24, 328-337.	4.1	42
83	Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine. <i>Journal of Psychopharmacology</i> , 2019, 33, 449-458.	2.0	24
84	Neuropsychological function at first episode in treatment-resistant psychosis: findings from the A†SOP-10 study. <i>Psychological Medicine</i> , 2019, 49, 2100-2110.	2.7	22
85	Psychiatric symptoms and risk of victimisation: a population-based study from Southeast London. <i>Epidemiology and Psychiatric Sciences</i> , 2019, 28, 168-178.	1.8	24
86	Childhood abuse and psychotic experiences â€“ evidence for mediation by adulthood adverse life events. <i>Epidemiology and Psychiatric Sciences</i> , 2019, 28, 300-309.	1.8	20
87	Negative Symptoms in Early-Onset Psychosis and Their Association With Antipsychotic Treatment Failure. <i>Schizophrenia Bulletin</i> , 2019, 45, 69-79.	2.3	47
88	Real-World Outcomes in the Management of Refractory Psychosis. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	1.1	6
89	Validation of an algorithm-based definition of treatment resistance in patients with schizophrenia. <i>Schizophrenia Research</i> , 2018, 197, 294-297.	1.1	16
90	Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. <i>Nature Genetics</i> , 2018, 50, 381-389.	9.4	1,332

#	ARTICLE	IF	CITATIONS
91	41. RECONSIDERING THE EVIDENCE FOR CLOZAPINE FOR TREATMENT REFRACTORY SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S66-S66.	2.3	0
92	Antipsychotic polypharmacy prescribing and risk of hospital readmission. Psychopharmacology, 2018, 235, 281-289.	1.5	29
93	S146. EFFECT OF CLOZAPINE ON REGIONAL CEREBRAL BLOOD FLOW IN TREATMENT-RESISTANT SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S382-S382.	2.3	0
94	Artistic creativity and risk for schizophrenia, bipolar disorder and unipolar depression: a Swedish population-based caseâ€“control study and sib-pair analysis. British Journal of Psychiatry, 2018, 212, 370-376.	1.7	34
95	Tobacco smoking is associated with psychotic experiences in the general population of South London. Psychological Medicine, 2018, 48, 123-131.	2.7	23
96	Utilising symptom dimensions with diagnostic categories improves prediction of time to first remission in first-episode psychosis. Schizophrenia Research, 2018, 193, 391-398.	1.1	7
97	Sodium valproate and clozapine induced neutropenia: A case control study using register data. Schizophrenia Research, 2018, 195, 267-273.	1.1	32
98	A systematic review and metaâ€“analysis of mental health service use in people who report psychotic experiences. Microbial Biotechnology, 2018, 12, 275-285.	0.9	30
99	41.3 COULD CLOZAPINE REDUCE VIOLENT OFFENDING?. Schizophrenia Bulletin, 2018, 44, S67-S67.	2.3	2
100	Editorsâ€™ Note: Paper Selected for the Mitchell B. Balter Award 2017. Journal of Clinical Psychopharmacology, 2018, 38, 316-316.	0.7	1
101	Hepatitis, Interstitial Nephritis, and Pancreatitis in Association With Clozapine Treatment. Journal of Clinical Psychopharmacology, 2018, 38, 520-527.	0.7	24
102	Constipation, ileus and medication use during clozapine treatment in patients with schizophrenia in Iceland. Nordic Journal of Psychiatry, 2018, 72, 497-500.	0.7	15
103	O3.7. EFFECT OF N-ACETYLCYSTEINE ON BRAIN GLUTAMATE LEVELS AND RESTING PERFUSION IN SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S81-S82.	2.3	0
104	Longâ€“term antipsychotic polypharmacy prescribing in secondary mental health care and the risk of mortality. Acta Psychiatrica Scandinavica, 2018, 138, 123-132.	2.2	25
105	T74. ACADEMIC ACHIEVEMENT AND SCHIZOPHRENIA: A META-ANALYSIS. Schizophrenia Bulletin, 2018, 44, S143-S143.	2.3	2
106	It is time to start taking tobacco seriously as a risk factor for psychosis: selfâ€“medication cannot explain the association. Acta Psychiatrica Scandinavica, 2018, 138, 3-4.	2.2	10
107	Biological Predictors of Clozapine Response: A Systematic Review. Frontiers in Psychiatry, 2018, 9, 327.	1.3	41
108	Effects of N-acetylcysteine on brain glutamate levels and resting perfusion in schizophrenia. Psychopharmacology, 2018, 235, 3045-3054.	1.5	20



#	ARTICLE	IF	CITATIONS
109	Capturing Rest-Activity Profiles in Schizophrenia Using Wearable and Mobile Technologies: Development, Implementation, Feasibility, and Acceptability of a Remote Monitoring Platform. JMIR MHealth and UHealth, 2018, 6, e188.	1.8	46
110	Epidemiology, impact, and predictors of treatment-resistant schizophrenia. , 2018, , .		0
111	Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review. BMC Psychiatry, 2017, 17, 12.	1.1	170
112	Predictors of Nonhospitalization and Functional Response in Clozapine Treatment. Journal of Clinical Psychopharmacology, 2017, 37, 148-154.	0.7	15
113	Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychological Medicine, 2017, 47, 1981-1989.	2.7	200
114	Polygenic Risk Score for Schizophrenia and Treatment-Resistant Schizophrenia. Schizophrenia Bulletin, 2017, 43, 1064-1069.	2.3	76
115	Subclinical psychotic experiences and subsequent contact with mental health services. BJPsych Open, 2017, 3, 64-70.	0.3	24
116	Clozapine-Associated Agranulocytosis Treatment With Granulocyte Colony-Stimulating Factor/Granulocyte-Macrophage Colony-Stimulating Factor. Journal of Clinical Psychopharmacology, 2017, 37, 441-446.	0.7	26
117	Educational Level, Underachievement, and General Mental Health Problems in 10,866 Adolescents. Academic Pediatrics, 2017, 17, 642-648.	1.0	9
118	Educational achievement in psychiatric patients and their siblings: a register-based study in 30 000 individuals in The Netherlands. Psychological Medicine, 2017, 47, 776-784.	2.7	33
119	Risk of diabetes and dyslipidemia during clozapine and other antipsychotic drug treatment of schizophrenia in Iceland. Nordic Journal of Psychiatry, 2017, 71, 496-502.	0.7	16
120	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. American Journal of Psychiatry, 2017, 174, 216-229.	4.0	685
121	Effects of a smoking ban on clozapine plasma concentrations in a nonsecure psychiatric unit. Therapeutic Advances in Psychopharmacology, 2017, 7, 79-83.	1.2	12
122	SU95. The Importance and Challenges of Longitudinal Studies Among Patients Diagnosed With Schizophrenia: Predicting Response to Antipsychotic Medication Using Strata. Schizophrenia Bulletin, 2017, 43, S195-S195.	2.3	1
123	The Use of Granulocyte Colony-Stimulating Factor in Clozapine Rechallenge. Journal of Clinical Psychopharmacology, 2017, 37, 600-604.	0.7	33
124	Longitudinal Epigenetic Analysis Of Clozapine Use In Treatment-Resistant Schizophrenia: Data From The Crestar Consortium. European Neuropsychopharmacology, 2017, 27, S463-S464.	0.3	1
125	Mortality and Self-Harm in Association With Clozapine in Treatment-Resistant Schizophrenia. American Journal of Psychiatry, 2017, 174, 990-998.	4.0	106
126	Patterns of illness and care over the 5Âyears following onset of psychosis in different ethnic groups; the GAP-5 study. Social Psychiatry and Psychiatric Epidemiology, 2017, 52, 1101-1111.	1.6	26



#	ARTICLE	IF	CITATIONS
127	Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia. <i>Molecular Psychiatry</i> , 2017, 22, 1502-1508.	4.1	75
128	27. Cannabis and Stimulant Misuse Do Not Completely Confound the Association Between Cigarette Smoking and Psychotic Experiences in Southeast London. <i>Schizophrenia Bulletin</i> , 2017, 43, S17-S18.	2.3	0
129	SU116. Longitudinal Epigenetic Analysis of Clozapine Use in Treatment-Resistant Schizophrenia. <i>Schizophrenia Bulletin</i> , 2017, 43, S203-S203.	2.3	1
130	The Association Between Comorbid Autism Spectrum Disorders and Antipsychotic Treatment Failure in Early-Onset Psychosis. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1233-e1241.	1.1	39
131	33. Clinical Predictors of 2 Types of Treatment Resistance in Patients With Psychosis. <i>Schizophrenia Bulletin</i> , 2017, 43, S20-S20.	2.3	1
132	Only a small proportion of patients with first episode psychosis come via prodromal services: a retrospective survey of a large UK mental health programme. <i>BMC Psychiatry</i> , 2017, 17, 308.	1.1	53
133	Prevalence and Predictors of Clozapine-Associated Constipation: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2016, 17, 863.	1.8	85
134	Gene polymorphisms potentially related to the pharmacokinetics of clozapine. <i>International Clinical Psychopharmacology</i> , 2016, 31, 179-184.	0.9	20
135	High educational performance is a distinctive feature of bipolar disorder: a study on cognition in bipolar disorder, schizophrenia patients, relatives and controls. <i>Psychological Medicine</i> , 2016, 46, 807-818.	2.7	74
136	SleepSight. , 2016, , .		15
137	Genetic overlap between type 2 diabetes and depression in Swedish and Danish twin registries. <i>Molecular Psychiatry</i> , 2016, 21, 903-909.	4.1	50
138	Clozapine treatment and discontinuation in Iceland: A national longitudinal study using electronic patient records. <i>Nordic Journal of Psychiatry</i> , 2016, 70, 450-455.	0.7	20
139	Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders. <i>Journal of Psychopharmacology</i> , 2016, 30, 436-443.	2.0	19
140	Predictors of long-term (≥ 6 months) antipsychotic polypharmacy prescribing in secondary mental healthcare. <i>Schizophrenia Research</i> , 2016, 174, 106-112.	1.1	24
141	Analysis of Intellectual Disability Copy Number Variants for Association With Schizophrenia. <i>JAMA Psychiatry</i> , 2016, 73, 963.	6.0	118
142	Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. <i>Psychological Medicine</i> , 2016, 46, 3231-3240.	2.7	202
143	Reasons for discontinuing clozapine: A cohort study of patients commencing treatment. <i>Schizophrenia Research</i> , 2016, 174, 113-119.	1.1	100
144	Pharmacological interventions for clozapine-induced sinus tachycardia. <i>The Cochrane Library</i> , 2016, 2016, CD011566.	1.5	9

#	ARTICLE	IF	CITATIONS
145	Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland. <i>BMC Psychiatry</i> , 2016, 16, 441.	1.1	35
146	Inverse association between urbanicity and treatment resistance in schizophrenia. <i>Schizophrenia Research</i> , 2016, 174, 150-155.	1.1	18
147	Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2016, 171, 215-224.	1.1	130
148	Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. <i>Lancet Psychiatry</i> , 2016, 3, 358-366.	3.7	105
149	Personalised approaches to pharmacotherapy for schizophrenia. <i>BJ Psych Advances</i> , 2016, 22, 78-86.	0.5	9
150	Substance use, medication adherence and outcome one year following a first episode of psychosis. <i>Schizophrenia Research</i> , 2016, 170, 311-317.	1.1	55
151	Sudden-Onset Catatonia Following Clozapine Withdrawal. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e899-e899.	1.1	10
152	Service users'™ and carers'™ views on research towards stratified medicine in psychiatry: a qualitative study. <i>BMC Research Notes</i> , 2015, 8, 489.	0.6	6
153	Clozapine use in childhood and adolescent schizophrenia: A nationwide population-based study. <i>European Neuropsychopharmacology</i> , 2015, 25, 857-863.	0.3	40
154	Schizophrenia patients with high intelligence: A clinically distinct sub-type of schizophrenia?. <i>European Psychiatry</i> , 2015, 30, 628-632.	0.1	18
155	Advancing paternal age and psychiatric disorders. <i>World Psychiatry</i> , 2015, 14, 91-93.	4.8	16
156	Tobacco and psychosis: Not quite a smoking gun. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 859-860.	1.3	2
157	Prevalence of serum <i>N</i> -methyl-d-aspartate receptor autoantibodies in refractory psychosis. <i>British Journal of Psychiatry</i> , 2015, 206, 164-165.	1.7	25
158	Establishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosis. <i>Pharmacogenomics Journal</i> , 2015, 15, 461-466.	0.9	21
159	Do premorbid and post-onset cognitive functioning differ between schizophrenia and bipolar disorder? A systematic review and meta-analysis. <i>Psychological Medicine</i> , 2015, 45, 381-394.	2.7	105
160	Does tobacco use cause psychosis? Systematic review and meta-analysis. <i>Lancet Psychiatry</i> , 2015, 2, 718-725.	3.7	240
161	The aetiology of schizophrenia: what have the Swedish Medical Registers taught us?. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2015, 50, 1471-1479.	1.6	12
162	Antipsychotic medication in schizophrenia: a review. <i>British Medical Bulletin</i> , 2015, 114, 169-179.	2.7	356

#	ARTICLE	IF	CITATIONS
163	Extracting antipsychotic polypharmacy data from electronic health records: developing and evaluating a novel process. <i>BMC Psychiatry</i> , 2015, 15, 166.	1.1	45
164	Tobacco use and psychosis: missing the risk of bias assessment and other methodological considerations – Authors' reply. <i>Lancet Psychiatry</i> , 2015, 2, 865-866.	3.7	0
165	Optimizing Outcomes in Clozapine Rechallenge Following Neutropenia. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e1410-e1416.	1.1	44
166	Ivabradine, a novel treatment for clozapine-induced sinus tachycardia: a case series. <i>Therapeutic Advances in Psychopharmacology</i> , 2014, 4, 117-122.	1.2	15
167	The practical management of refractory schizophrenia - the Maudsley Treatment REview and Assessment Team service approach. <i>Acta Psychiatrica Scandinavica</i> , 2014, 130, 427-438.	2.2	38
168	Delayed school progression and mental health problems in adolescence: a population-based study in 10,803 adolescents. <i>BMC Psychiatry</i> , 2014, 14, 244.	1.1	9
169	Cardiovascular drug use and mortality in patients with schizophrenia or bipolar disorder: a Danish population-based study. <i>Psychological Medicine</i> , 2014, 44, 1625-1637.	2.7	65
170	Cannabis use, gender and age of onset of schizophrenia: Data from the AESOP study. <i>Psychiatry Research</i> , 2014, 215, 528-532.	1.7	80
171	SYSTEMATIC REVIEW AND META-ANALYSIS ON ASSOCIATIONS BETWEEN TOBACCO SMOKING AND BOTH THE DIAGNOSIS AND THE CLINICAL SYMPTOMS OF PSYCHOSIS?. <i>Schizophrenia Research</i> , 2014, 153, S8.	1.1	1
172	Pre-morbid fertility in psychosis: Findings from the AESOP first episode study. <i>Schizophrenia Research</i> , 2014, 156, 168-173.	1.1	4
173	CIGARETTE SMOKING IS EQUALLY STRONGLY ASSOCIATED WITH PSYCHOTIC-LIKE EXPERIENCES AS CANNABIS USE. <i>Schizophrenia Research</i> , 2014, 153, S9.	1.1	0
174	Daily Use, Especially of High-Potency Cannabis, Drives the Earlier Onset of Psychosis in Cannabis Users. <i>Schizophrenia Bulletin</i> , 2014, 40, 1509-1517.	2.3	364
175	Cannabis Use is a Better Indicator of Poor Mental Health in Women Than in Men: A Cross-Sectional Study in Young Adults from the General Population. <i>Community Mental Health Journal</i> , 2014, 50, 823-830.	1.1	12
176	COGNITIVE TRAJECTORY BETWEEN AGES 10, 13 AND 18 AND RISK FOR PSYCHOSIS IN ADULTHOOD: A SWEDISH LONGITUDINAL COHORT STUDY. <i>Schizophrenia Research</i> , 2014, 153, S81.	1.1	0
177	Making clozapine safer: current perspectives on improving its tolerability. <i>Future Neurology</i> , 2014, 9, 313-322.	0.9	11
178	Change in cannabis use in the general population: A longitudinal study on the impact on psychotic experiences. <i>Schizophrenia Research</i> , 2014, 157, 266-270.	1.1	27
179	Clozapine: Gold Standard Treatment for Refractory Schizophrenia: Now or Never?. , 2014, , 81-91.		2
180	Opening Pandora's box in the UK: a hypothetical pharmacogenetic test for clozapine. <i>Pharmacogenomics</i> , 2013, 14, 1907-1914.	0.6	11

#	ARTICLE	IF	CITATIONS
181	Fecundity of Patients With Schizophrenia, Autism, Bipolar Disorder, Depression, Anorexia Nervosa, or Substance Abuse vs Their Unaffected Siblings. <i>JAMA Psychiatry</i> , 2013, 70, 22.	6.0	284
182	Gender difference in age at onset of schizophrenia: a meta-analysis. <i>Psychological Medicine</i> , 2013, 43, 155-167.	2.7	136
183	Cigarette smoking and cannabis use are equally strongly associated with psychotic-like experiences: a cross-sectional study in 1929 young adults. <i>Psychological Medicine</i> , 2013, 43, 2393-2401.	2.7	43
184	Decline in Cognitive Performance Between Ages 13 and 18 Years and the Risk for Psychosis in Adulthood. <i>JAMA Psychiatry</i> , 2013, 70, 261.	6.0	99
185	Preterm Birth and Psychiatric Disorders in Young Adult Life. <i>Archives of General Psychiatry</i> , 2012, 69, E1-8.	13.8	388
186	Granulocyte Colony Stimulating Factor (G-CSF) can allow treatment with clozapine in a patient with severe Benign Ethnic Neutropaenia (BEN): a case report. <i>Journal of Psychopharmacology</i> , 2012, 26, 1280-1282.	2.0	19
187	Review: premorbid IQ is inversely associated with future risk of schizophrenia. <i>Evidence-Based Mental Health</i> , 2012, 15, 33-33.	2.2	0
188	Schizophrenia, 3rd edn. Edited by D. R. Weinberger and P. J. Harrison. (Pp. 736; £131.00; ISBN:) 0 00 000 000 0	2.7	0
189	How Genes and Environmental Factors Determine the Different Neurodevelopmental Trajectories of Schizophrenia and Bipolar Disorder. <i>Schizophrenia Bulletin</i> , 2012, 38, 209-214.	2.3	161
190	Poster #4 SEX DIFFERENCES IN PLASMA CLOZAPINE/NORCLOZAPINE AND OLANZAPINE CONCENTRATIONS IN CLINICAL PRACTICE: DATA FROM A THERAPEUTIC DRUG MONITORING SERVICE. <i>Schizophrenia Research</i> , 2012, 136, S186.	1.1	1
191	Poster #93 CARDIOVASCULAR DRUG USE IN PATIENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER. <i>Schizophrenia Research</i> , 2012, 136, S219.	1.1	0
192	Is there a link between childhood trauma, cognition, and amygdala and hippocampus volume in first-episode psychosis?. <i>Schizophrenia Research</i> , 2012, 137, 73-79.	1.1	96
193	Superior intellectual ability in schizophrenia: Neuropsychological characteristics. <i>Neuropsychology</i> , 2012, 26, 181-190.	1.0	46
194	Advancing Maternal Age Is Associated With Increasing Risk for Autism: A Review and Meta-Analysis. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2012, 51, 477-486.e1.	0.3	233
195	Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged 65 years and over: data from a therapeutic drug monitoring service, 1996-2010. <i>Human Psychopharmacology</i> , 2012, 27, 277-283.	0.7	25
196	A systematic review and meta-analysis of the fertility of patients with schizophrenia and their unaffected relatives. <i>Acta Psychiatrica Scandinavica</i> , 2011, 123, 98-106.	2.2	121
197	Estimates of how many cannabis users need to be prevented in order to prevent one case of schizophrenia. <i>Evidence-Based Mental Health</i> , 2010, 13, 57-57.	2.2	1
198	Excellent school performance at age 16 and risk of adult bipolar disorder: national cohort study. <i>British Journal of Psychiatry</i> , 2010, 196, 109-115.	1.7	294

#	ARTICLE	IF	CITATIONS
199	Clozapine Rechallenge Following Clozapine-Induced Pericarditis. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 959-961.	1.1	20
200	Epigenetics, genomic mutations and cognitive function. <i>Cognitive Neuropsychiatry</i> , 2009, 14, 377-390.	0.7	36
201	Clinical Handbook of Schizophrenia. Edited by Kim T. Mueser & Dilip V. Jeste, Guilford Press. 2008. US\$75.00 (hb). 650pp. ISBN: 9781593856526. <i>British Journal of Psychiatry</i> , 2009, 195, 89-89.	1.7	1
202	Lifetime reproductive output over two generations in patients with psychosis and their unaffected siblings: the Uppsala 1915-1929 Birth Cohort Multigenerational Study. <i>Psychological Medicine</i> , 2009, 39, 1667.	2.7	53
203	Neuropsychological correlates of eye movement abnormalities in schizophrenic patients and their unaffected relatives. <i>Psychiatry Research</i> , 2009, 168, 193-197.	1.7	13
204	Specificity of the jump-to-conclusions bias in deluded patients. <i>British Journal of Clinical Psychology</i> , 2008, 47, 239-244.	1.7	35
205	Pregnancy outcomes of mothers with bipolar disorders. <i>Journal of Affective Disorders</i> , 2008, 107, S25.	2.0	0
206	Population-based Cohort Studies on Premorbid Cognitive Function in Schizophrenia. <i>Epidemiologic Reviews</i> , 2008, 30, 77-83.	1.3	62
207	Scholastic achievement at age 16 and risk of schizophrenia and other psychoses: a national cohort study. <i>Psychological Medicine</i> , 2008, 38, 1133-1140.	2.7	106
208	Feeling the pressure: work stress and mental health. <i>Psychological Medicine</i> , 2007, 37, 1073-1074.	2.7	17
209	Adverse pregnancy outcomes in mothers with affective psychosis. <i>Bipolar Disorders</i> , 2007, 9, 305-309.	1.1	60
210	Psychiatry in Cambodia: the phoenix rises from the ashes. <i>International Psychiatry: Bulletin of the Board of International Affairs of the Royal College of Psychiatrists</i> , 2007, 4, 37-38.	0.2	3
211	Psychiatry in Cambodia: the phoenix rises from the ashes. <i>International Psychiatry: Bulletin of the Board of International Affairs of the Royal College of Psychiatrists</i> , 2007, 4, 37-38.	0.2	2
212	Is there an association between the COMT gene and P300 endophenotypes?. <i>European Psychiatry</i> , 2006, 21, 70-73.	0.1	40
213	Duration of untreated psychosis and ethnicity in the Å†SOP first-onset psychosis study. <i>Psychological Medicine</i> , 2006, 36, 239-247.	2.7	64
214	The relationship between eye movement and brain structural abnormalities in patients with schizophrenia and their unaffected relatives. <i>Journal of Psychiatric Research</i> , 2006, 40, 589-598.	1.5	12
215	Maternal Smoking During Pregnancy and School Performance at Age 15. <i>Epidemiology</i> , 2006, 17, 524-530.	1.2	109
216	¿Hay una asociaci3n entre el gen de la COMT y los endofenotipos de la onda P300?. <i>European Psychiatry (Ed Espa±ola)</i> , 2006, 13, 244-248.	0.0	0

#	ARTICLE	IF	CITATIONS
217	Good financial management does not lead to better services. BMJ: British Medical Journal, 2006, 333, 920.1.	2.4	0
218	Saccadic distractibility is elevated in schizophrenia patients, but not in their unaffected relatives. Psychological Medicine, 2005, 35, 1727-1736.	2.7	18
219	Regional volume deviations of brain structure in schizophrenia and psychotic bipolar disorder. British Journal of Psychiatry, 2005, 186, 369-377.	1.7	206
220	Eye tracking in schizophrenia: Does the antisaccade task measure anything that the smooth pursuit task does not?. Psychiatry Research, 2005, 136, 181-188.	1.7	18
221	Intellectual functioning in schizophrenia: a marker of neurodevelopmental damage?. Journal of Intellectual Disability Research, 2004, 48, 519-523.	1.2	15
222	Clozapine-induced obsessive-compulsive symptoms. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2004, 28, 1209.	2.5	10
223	Do schizophrenic patients who managed to get to university have a non-developmental form of illness?. Psychological Medicine, 2002, 32, 535-544.	2.7	22
224	Behavior Therapy Attenuates Clozapine-Induced Obsessions and Compulsions. Journal of Clinical Psychiatry, 2002, 63, 1179-1180.	1.1	17
225	Paradoxes in creativity and psychiatric conditions. , 0, , 289-300.		4
226	Clozapine Treatment and Risk of COVID-19. SSRN Electronic Journal, 0, , .	0.4	2
227	Prescribing clozapine in the UK: Quality improvement issues identified by clinical audit. Journal of Psychopharmacology, 0, , 026988112211040.	2.0	1